Effect of Ginkgo biloba extract on oxidative metabolism of valproic acid in hepatic microsomes from donors with the CYP2C9*1/*1 genotype

Canadian Journal of Physiology and Pharmacology

Volumn 85, Issue 9, 2007, Pages 848-855

  Numa, Andrew M ^a   Abbott, Frank S ^a   Chang, Thomas K H ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Bilobalide; Cytochrome P450; Flavonol; Ginkgo biloba; Ginkgolide; Valproic acid

Indexed keywords

BILOBALIDE; CYTOCHROME P450 2A6; CYTOCHROME P450 2B6; CYTOCHROME P450 2C9; DRUG METABOLITE; FLAVONOID GLYCOSIDE; GINKGO BILOBA EXTRACT; GINKGOLIDE A; GINKGOLIDE B; GINKGOLIDE C; GINKGOLIDE J; GLYCOSIDE; ISORHAMNETIN 3 O RUTINOSIDE; NICOTIFLORIN; QUERCETIN 3 O RUTINOSIDE; TERPENE DERIVATIVE; TERPENE TRILACTONE; UNCLASSIFIED DRUG; VALPROIC ACID;

AEROBIC METABOLISM; ARTICLE; CONTROLLED STUDY; DRUG METABOLISM; GENOTYPE; GINKGO BILOBA; HUMAN; HUMAN TISSUE; LIVER MICROSOME; PRIORITY JOURNAL;

ADULT; AGED; ANTICONVULSANTS; ARYL HYDROCARBON HYDROXYLASES; CATALYSIS; DNA, COMPLEMENTARY; FEMALE; GENOTYPE; GINKGO BILOBA; HUMANS; MALE; MICROSOMES, LIVER; MIDDLE AGED; MIXED FUNCTION OXYGENASES; OXIDATION-REDUCTION; OXIDOREDUCTASES, N-DEMETHYLATING; PLANT EXTRACTS; VALPROIC ACID;

EID: 36549024380     PISSN: 00084212     EISSN: None     Source Type: Journal    
DOI: 10.1139/Y06-085     Document Type: Article

References (39)

1. Anari, M.R., Burton, R.W., Gopaul, S., and Abbott, F.S. 2000. Metabolic profiling of valproic acid by cDNA-expressed human cytochrome P450 enzymes using negative-ion chemical ionization gas chromatography-mass spectrometry. J. Chromatogr. B Biomed. Sci. Appl. 742: 217-227. doi:10.1016/S0378-4347(00) 00161-4.
2. Baillie, T.A. 1988. Metabolic activation of valproic acid and drug-mediated hepatotoxicity. Role of the terminal olefin, 2-n-propyl-4- pentenoic acid. Chem. Res. Toxicol. 1: 195-199. doi:10.1021/ tx00004a001.
3. Bryant, A.E., III, and Dreifuss, F.E. 1996. Valproic acid hepatic fatalities. III. U.S. experiences since 1986. Neurology, 46: 465-469.
4. Chang, T.K.H., Weber, G.F., Crespi, C.L., and Waxman, D.J. 1993. Differential activation of cyclophosphamide and ifosphamide by cytochromes P-450 2B and 3A in human liver microsomes. Cancer Res. 53: 5629-5637.
5. Chang, T.K.H., Chen, J., and Teng, X.W. 2006. Distinct role of bilobalide and ginkgolide A in the modulation of rat CYP2B1 and CYP3A23 gene expression by Ginkgo biloba extract in cultured hepatocytes. Drug Metab. Dispos. 34: 234-242.
6. Ding, X., and Kaminsky, L.S. 2003. Human extrahepatic cytochromes P450: function in xenobiotic metabolism and tissue-selective chemical toxicity in the respiratory and gastrointestinal tracts. Annu. Rev. Pharmacol. Toxicol. 43: 149-173. doi:10.1146/annurev.pharmtox.43.100901.140251.
7. Donato, M.T., and Castell, J.V. 2003. Strategies and molecular probes to investigate the role of cytochrome P450 in drug metabolism. Focus on in vitro studies. Clin. Pharmacokinet. 42: 153-178. doi:10. 2165/00003088- 200342020-00004.
8. Dreifuss, F.E., Santilli, N., Langer, D.H., Sweeney, K.P., Moline, K.A., and Menander, K.B. 1987. Valproic acid hepatic fatalities: a retrospective review. Neurology, 37: 379-385.
9. Dreifuss, F.E., Langer, D.H., Moline, K.A., and Maxwell, J.E. 1989. Valproic acid hepatic fatalities. II. U.S. experience since 1984. Neurology, 39: 201-207.
10. Gaudineau, C., Beckerman, R., Welbourn, S., and Auclair, K. 2004. Inhibition of human P450 enzymes by multiple constituents of the Ginkgo biloba extract. Biochem. Biophys. Res. Commun. 318: 1072-1078. doi:10.1016/j.bbrc.2004.04.139.
11. Gottlicher, M., Minucci, S., Zhu, P., Kramer, O.H., Schimpf, A., Giavara, S., et al. 2001. Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells. EMBO J. 20: 6969-6978. doi:10.1093/emboj/20.24.6969.
12. Greenblatt, D.J., von Moltke, L.L., Luo, Y., Perloff, E.S., Horan, K.A., Bruce, A., et al. 2006. Ginkgo biloba does not alter clearance of flurbiprofen, a cytochrome P450-2C9 substrate. J. Clin. Pharmacol. 46: 214-221.
13. Ho, P.C., Abbott, F.S., Zanger, U.M., and Chang, T.K.H. 2003. Influence of CYP2C9 genotypes on the formation of a hepatotoxic metabolite of valproic acid in human liver microsomes. Pharmacogenomics J. 3: 335-342. doi:10.1038/sj.tpj.6500210.
14. Jiang, X., Williams, K.M., Liauw, W.S., Ammit, A.J., Roufogalis, B.D., Duke, C.C., Day, R.O., and McLachlan, A.J. 2005. Effect of ginkgo and ginger on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects. Br. J. Clin. Pharmacol. 59: 425-432. doi:10.1111/j.1365-2125.2005.02322.x.
15. Kassahun, K., Farrell, K., and Abbott, F.S. 1991. Identification and characterization of the glutathione and N-acetylcysteine conjugates of (E)-2-propyl-2,4-pentadienoic acid, a toxic metabolite of valproic acid, in rats and humans. Drug Metab. Dispos. 19: 525-535.
16. Kesterson, J.W., Granneman, G.R., and Machinist, J.M. 1984. The hepatotoxicity of valproic acid and its metabolites in rats. I. Toxicologic, biochemical and histopathologic studies. Hepatology, 4: 1143-1152.
17. Kiang, T.K.L., Ho, P.C., Anari, M.R., Tong, V., Abbott, F.S., and Chang, T.K.H. 2006. Contribution of CYP2C9, CYP2A6, and CYP2B6 to valproic acid metabolism in hepatic microsomes from individuals with the CYP2C9*1/ *1 genotype. Toxicol. Sci. 94: 261-271. doi:10.1093/toxsci/kfl096.
18. Kingsley, E., Gray, P., Tolman, K.G., and Tweedale, R. 1983. The toxicity of metabolites of sodium valproate in cultured hepatocytes. J. Clin. Pharmacol. 23: 178-185.
19. Kirchheiner, J., and Brockmoller, J. 2005. Clinical consequences of cytochrome P450 2C9 polymorphisms. Clin. Pharmacol. Ther. 77: 1-16. doi:10.1016/j.clpt.2004.08.009.
20. Kressmann, S., Muller, W.E., and Blume, H.H. 2002. Pharmaceutical quality of different Ginkgo biloba brands. J. Pharm. Pharmacol. 54: 661-669. doi:10.1211/0022357021778970.
21. Lehrman, G., Hogue, I.B., Palmer, S., Jennings, C., Spina, C.A., Wiegand, A., et al. 2005. Depletion of latent HIV-1 infection in vivo: a proof-of-concept study. Lancet, 366: 549-555. doi:10. 1016/S0140-6736(05)67098-5.
22. Loscher, W. 1999. Valproate: a reappraisal of its pharmacodynamic properties and mechanisms of action. Prog. Neurobiol. 58: 31-59. doi:10.1016/S0301-0082(98)00075-6.
23. Loscher, W. 2002. Basic pharmacology of valproate: a review after 35 years of clinical use for the treatment of epilepsy. CNS Drugs, 16: 669-694.
24. Loscher, W., Nau, H., Wahnschaffe, U., Honack, D., Rundfeldt, C., Wittfoht, W., and Bojic, U. 1993. Effects of valproate and E-2-en-valproate on functional and morphological parameters of rat liver. II. Influence of phenobarbital comedication. Epilepsy Res. 15: 113-131. doi:10.1016/0920-1211(93)90092-L.
25. Maclennan, K.M., Darlington, C.L., and Smith, P.F. 2002. The CNS effects of Ginkgo biloba extracts and ginkgolide B. Prog. Neurobiol. 67: 235-257. doi:10.1016/S0301-0082(02)00015-1.
26. Minucci, S., and Pelicci, P.G. 2006. Histone deacetylase inhibitors and the promise of epigenetic (and more) treatment of cancer. Nat. Rev. Cancer, 6: 38-51. doi:10.1038/nrc1779.
27. Mohutsky, M.A., Anderson, G.D., Miller, J.W., and Elmer, G.W. 2006. Ginkgo biloba: evaluation of CYP2C9 drug interactions in vitro and in vivo. Am. J. Ther. 13: 24-31. doi:10.1097/01. mjt.0000143695.68285.31.
28. Nau, H., and Loscher, W. 1986. Pharmacologic evaluation of various metabolites and analogs of valproic acid: teratogenic potencies in mice. Fundam. Appl. Toxicol. 6: 669-676. doi:10.1016/ 0272-0590(86)90180-6.
29. Phiel, C.J., Zhang, F., Huang, E.Y., Guenther, M.G., Lazar, M.A., and Klein, P.S. 2001. Histone deacetylase is a direct target of valproic acid, a potent anticonvulsant, mood stabilizer, and teratogen. J. Biol. Chem. 276: 36734-36741. doi:10.1074/jbc. M101287200.
30. Prickett, K.S., and Baillie, T.A. 1984. Metabolism of valproic acid by hepatic microsomal cytochrome P-450. Biochem. Biophys. Res. Commun. 122: 1166-1173. doi:10.1016/0006-291X(84) 91214-2.
31. Rettie, A.E., and Jones, J.P. 2005. Clinical and toxicological relevance of CYP2C9: drug-drug interactions and pharmacogenetics. Annu. Rev. Pharmacol. Toxicol. 45: 477-494. doi:10.1146/ annurev.pharmtox.45.120403.095821.
32. 4-VPA, a toxic metabolite of valproic acid. Science (Washington), 235: 890-893. doi:10.1126/science.3101178.
33. Sadeque, A.J.M., Fisher, M.B., Korzekwa, K.R., Gonzalez, F.J., and Rettie, A.E. 1997. Human CYP2C9 and CYP2A6 mediate formation of the hepatotoxin 4-ene-valproic acid. J. Pharmacol. Exp. Ther. 283: 698-703.
34. Tang, W., Borel, A.G., Fujimiya, T., and Abbott, F.S. 1995. Fluorinated analogues as mechanistic probes in valproic acid hepatotoxicity: hepatic microvesicular steatosis and glutathione status. Chem. Res. Toxicol. 8: 671-682. doi:10.1021/tx00047a006.
35. van Beek, T.A. 2002. Chemical analysis of Ginkgo biloba leaves and extracts. J. Chromatogr. A. 967: 21-55. doi:10.1016/S0021-9673(02)00172- 3.
36. Walle, T. 2004. Absorption and metabolism of flavonoids. Free Radic. Biol. Med. 36: 829-837. doi:10.1016/j.freeradbiomed.2004. 01.002.
37. Wojcicki, J., Gawronska-Szklarz, G., Bieganowski, W., Patalan, M., Smulski, H., Samochowiec, L., and Zakrzewski, J. 1995. Comparative pharmacokinetics and bioavailability of flavonoid glycosides of Ginkgo biloba after a single oral administration of three formulations to healthy volunteers. Mater. Med. Pol. 27: 141-146.
38. Yamazaki, H., Inui, Y., Yun, C.H., Mimura, M., Guengerich, F.P., and Shimada, T. 1992. Cytochrome P450 2E1 and 2A6 enzymes as major catalysts for metabolic activation of N-nitrosodialkylamines and tobacco-related nitrosamines in human liver microsomes. Carcinogenesis, 13: 1789-1794.
39. Zheng, J.J. 1993. Metabolism and pharmacokinetic studies of valproic acid using stable isotope techniques. M.Sc. Thesis. The University of British Columbia. Vancouver, Canada.